Volume 9, Issue 9, Pages 866-872 (September 2008) Risk factors for joint symptoms in patients enrolled in the ATAC trial: a retrospective, exploratory analysis Ivana Sestak, PhD, Prof Jack Cuzick, PhD, Francisco Sapunar, MD, Prof Richard Eastell, MD, Prof John F Forbes, FRACS, Angelo R Bianco, MD, Aman U Buzdar, MD The Lancet Oncology Volume 9, Issue 9, Pages 866-872 (September 2008) DOI: 10.1016/S1470-2045(08)70182-7 Copyright © 2008 Elsevier Ltd Terms and Conditions
Figure 1 Patients (%) developing joint symptoms at or before a specified follow-up time during active treatment according to treatment first received in women without joint symptoms at entry (study population) The Lancet Oncology 2008 9, 866-872DOI: (10.1016/S1470-2045(08)70182-7) Copyright © 2008 Elsevier Ltd Terms and Conditions
Figure 2 Smoothed annual hazard rates (%) of newly reported joint symptoms during active treatment according to treatment first received in women without joint symptoms at entry (study population) The Lancet Oncology 2008 9, 866-872DOI: (10.1016/S1470-2045(08)70182-7) Copyright © 2008 Elsevier Ltd Terms and Conditions